Teja Reddi

Teja R. is an accomplished professional in the biotechnology and life sciences sectors, currently serving as Senior Director of Strategy and Operations at BridgeBio since April 2023. In this role, Teja R. successfully led negotiations for the QED-KKC deal, securing a $100 million upfront payment and facilitating access to infigratinib for the Japanese community affected by skeletal dysplasias. Prior to this, Teja R. held leadership positions at Clover Biopharmaceuticals and Mass General Brigham, focusing on business development and corporate strategy within early-stage biotechnology and healthcare innovation. With a solid foundation in life sciences consulting from Decision Resources Group and a Ph.D. in Immunology from Harvard Medical School, Teja R. combines extensive industry experience with advanced academic expertise in the field.